119 related articles for article (PubMed ID: 23811443)
1. Identification of Sulfamoylbenzamide derivatives as selective Cathepsin D inhibitors.
Ahmed W; Khan IA; Arshad MN; Siddiqui WA; Haleem MA; Azim MK
Pak J Pharm Sci; 2013 Jul; 26(4):687-90. PubMed ID: 23811443
[TBL] [Abstract][Full Text] [Related]
2. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM
Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344
[TBL] [Abstract][Full Text] [Related]
3. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A
J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825
[TBL] [Abstract][Full Text] [Related]
5. High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II.
Nöteberg D; Schaal W; Hamelink E; Vrang L; Larhed M
J Comb Chem; 2003; 5(4):456-64. PubMed ID: 12857114
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.
Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996
[TBL] [Abstract][Full Text] [Related]
7. Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases.
Binkert C; Frigerio M; Jones A; Meyer S; Pesenti C; Prade L; Viani F; Zanda M
Chembiochem; 2006 Jan; 7(1):181-6. PubMed ID: 16307463
[TBL] [Abstract][Full Text] [Related]
8. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.
Nöteberg D; Hamelink E; Hultén J; Wahlgren M; Vrang L; Samuelsson B; Hallberg A
J Med Chem; 2003 Feb; 46(5):734-46. PubMed ID: 12593654
[TBL] [Abstract][Full Text] [Related]
10. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
Dali B; Keita M; Megnassan E; Frecer V; Miertus S
Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
[TBL] [Abstract][Full Text] [Related]
11. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a structure-based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D.
Carroll CD; Johnson TO; Tao S; Lauri G; Orlowski M; Gluzman IY; Goldberg DE; Dolle RE
Bioorg Med Chem Lett; 1998 Nov; 8(22):3203-6. PubMed ID: 9873703
[TBL] [Abstract][Full Text] [Related]
13. The potential of P1 site alterations in peptidomimetic protease inhibitors as suggested by virtual screening and explored by the use of C-C-coupling reagents.
Weik S; Luksch T; Evers A; Böttcher J; Sotriffer CA; Hasilik A; Löffler HG; Klebe G; Rademann J
ChemMedChem; 2006 Apr; 1(4):445-57. PubMed ID: 16892380
[TBL] [Abstract][Full Text] [Related]
14. New potent C2-symmetric malaria plasmepsin I and II inhibitors.
Oscarsson K; Oscarson S; Vrang L; Hamelink E; Hallberg A; Samuelsson B
Bioorg Med Chem; 2003 Apr; 11(7):1235-46. PubMed ID: 12628651
[TBL] [Abstract][Full Text] [Related]
15. Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.
Zogota R; Kinena L; Withers-Martinez C; Blackman MJ; Bobrovs R; Pantelejevs T; Kanepe-Lapsa I; Ozola V; Jaudzems K; Suna E; Jirgensons A
Eur J Med Chem; 2019 Feb; 163():344-352. PubMed ID: 30529637
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs.
Johansson PO; Chen Y; Belfrage AK; Blackman MJ; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
J Med Chem; 2004 Jun; 47(13):3353-66. PubMed ID: 15189032
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
Gupta D; Yedidi RS; Varghese S; Kovari LC; Woster PM
J Med Chem; 2010 May; 53(10):4234-47. PubMed ID: 20438064
[TBL] [Abstract][Full Text] [Related]
18. [Selective inhibitors of plasmepsin II from Plasmodium falciparum based on pepstatin].
Rumsh LD; Mikhaĭlova AG; Mikhura IV; Prudchenko IA; Chikin LD; Mikhaleva II; Kaliberda EN; Dergousova NI; Mel'nikov EE; Formanovskiĭ AA
Bioorg Khim; 2008; 34(6):739-46. PubMed ID: 19088746
[TBL] [Abstract][Full Text] [Related]
19. Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design.
McKay PB; Peters MB; Carta G; Flood CT; Dempsey E; Bell A; Berry C; Lloyd DG; Fayne D
Bioorg Med Chem Lett; 2011 Jun; 21(11):3335-41. PubMed ID: 21531557
[TBL] [Abstract][Full Text] [Related]
20. Antiplasmodial activities of 4-aminoquinoline-statine compounds.
Vaiana N; Marzahn M; Parapini S; Liu P; Dell'Agli M; Pancotti A; Sangiovanni E; Basilico N; Bosisio E; Dunn BM; Taramelli D; Romeo S
Bioorg Med Chem Lett; 2012 Sep; 22(18):5915-8. PubMed ID: 22884991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
